Published online: November 14, 2017
The UK was the first country to legalise mitochondrial donation in October 2015 (1). In 2016, the first three-parent baby was born in Mexico (2) and the US Food and Drug Administration declared that further research on mitochondrial donation is ethically permissible (3). It has now become an important issue, raising as it does, the spectre of “genetically modified designer babies”.
Mitochondrial manipulation technology (MMT) or mitochondrial donation is a unique form of in-vitro fertilisation in which the prospective baby’s mitochondrial DNA (mtDNA) comes from a third biological parent (4). Present in cell cytoplasm, mtDNA is inherited via the maternal side; thus, children born of women with mutations in mtDNA will inherit the mutations. MMT is used when mothers carry genetic mitochondrial diseases and conventional in-vitro fertilisation techniques do not work.
There are mainly two methods of mitochondrial transfer:
Using human embryos for in-vitro research is controversial. Opponents consider it unethical to destroy the unwanted embryos generated during research; they argue that an embryo has personhood, and as such, has equal rights as an adult.
Financial compensation of the egg donor is another ethical issue. Egg donation requires powerful hormone therapy, stoppage of normal ovarian functions, superovulation for the woman to provide eggs, hormones to release matured eggs from the ovaries and minor surgery to remove them from the body. The financial compensation offered will always be less than the risk undertaken. The process may even lead to death, which cannot be compensated for.
People believe MMT “could have uncontrollable and unforeseeable consequences, affecting future generations and modifying genetic heritage in an irreversible way, inevitably affecting the human species as a whole” (7). Also pertinent is the impact on the child’s sense of identity and psychological / emotional well-being, when compared to two-parent babies. Although, the donor egg is said to contribute only 1% to the genetic make-up of the child, there are still three identifiable parents in the genetic material (8). Further, although MMT has been successful in mice and monkeys, its safety cannot be directly extrapolated to humans.
Two pertinent issues are the risk to the embryo if there is a mismatch between the mtDNA haplotype of the donor and that of the intending mother; and the consequences of some defective mitochondria remaining attached to the nucleus during the process of transfer. The Department of Health of UK recommends that three-parent children be monitored for their current and future well-being. It remains to be seen whether it is ethically acceptable to enroll the children in such studies; if follow-up will extend to future generations; and whether incentives will be required to encourage continued participation (9).
Neha Dahiya (email@example.com), Senior Resident, Department of Community Medicine, Maulana Azad Medical College, New Delhi, India; Suneela Garg (firstname.lastname@example.org) Director, Professor and Head, Department of Community Medicine, Maulana Azad Medical College, New Delhi, India